A R T I C L E S
Tse et al.
These approaches to the central problem of translating nucleic
acids into corresponding synthetic compounds are relatively
recent developments, and their ability to provide molecules with
desired functional properties will depend on their applicability
to appropriately sized libraries of synthetic structures. Past
efforts to synthesize and evaluate libraries of synthetic small
molecules have resulted in the discovery of chemical genetic
probes that perturb specific cellular functions in vivo in a
temporally controlled, dose-dependent, and reversible manner,24-30
as well as the discovery of lead compounds for the development
of new therapeutic agents.31-33
Despite these attractive features, the availability and use of
small- and medium-sized macrocycles have been limited by the
challenges associated with their synthesis.31,34,59-62 Macrocy-
clization reactions can be very sensitive to small structural
variations within linear precursors,60,63 can be especially difficult
for small peptide substrates that form medium-sized macro-
cycles,61,64-66 and can be prone to multimeric side-products
arising from intermolecular bond formation.61,62 These chal-
lenges are magnified in a solid-phase library synthesis format
in which the removal of truncated, multimeric, and acyclic
byproducts from desired macrocycles (all of which are linked
to the same bead) can be difficult.
Macrocycles are of special interest for the development of
biologically active small molecules.34-46 The increased rigidity
of macrocyclic compounds can greatly decrease the entropic
cost of their binding to biological targets, resulting in higher
potential binding affinities and specificities than those of
corresponding linear compounds.34,36,41,47-53 In addition, mac-
rocyclic peptide-like structures can possess higher bioavailabil-
ity, membrane permeability, and resistance to in ViVo degrada-
tion than their linear counterparts.34,36,40,41,54-58 These advantages
likely account for the significant representation of macrocyclic
compounds among biologically active secondary metabolites.38,39
We hypothesized that several features of DNA-templated
synthesis could facilitate access to macrocycles. DNA-templated
synthesis is compatible with aqueous solvent,67 extremely low
(nM) reactant concentrations,9 and selection-based purification
methods for bond formation or bond cleavage that are not
available to solid-phase synthesis10s all factors that could
promote macrocycle formation or facilitate macrocycle isolation.
We also anticipated that the ability of base pairing to hold
together relevant reactive groups at elevated effective molarities
during the macrocyclization step would further assist the ring
closure reaction. Indeed, these features enabled the successful
DNA-templated synthesis and model in Vitro selection of a pilot
library of 65 macrocycles.15
Here, we report the DNA-templated synthesis of a large
library of synthetic macrocycles suitable for in Vitro selection.
Achieving this goal required several significant methodological
advances. We developed a more robust and efficient library
synthesis route to these compounds and conducted a thorough
study of the compatibility of 36 building blocks and eight
scaffolds in DNA-templated macrocycle synthesis. Guided by
our previous studies on template secondary structure,68 we
designed a new set of DNA codons to support large-scale library
synthesis. We confirmed the efficacy, quality, and sequence
fidelity of our library synthesis method by examining a series
of small-molecule sublibraries with PAGE and high resolution
(20) Melkko, S.; Scheuermann, J.; Dumelin, C. E.; Neri, D. Nat. Biotechnol.
2004, 22, 568–74.
(21) Dumelin, C. E.; Scheuermann, J.; Melkko, S.; Neri, D. Bioconjug.
Chem. 2006, 17, 366–70.
(22) Melkko, S.; Zhang, Y.; Dumelin, C. E.; Scheuermann, J.; Neri, D.
Angew. Chem., Int. Ed. 2007, 46, 4671–4.
(23) Scheuermann, J.; Dumelin, C. E.; Melkko, S.; Zhang, Y.; Mannocci,
L.; Jaggi, M.; Sobek, J.; Neri, D. Bioconjug. Chem. 2008, 19, 778–
85.
(24) Schreiber, S. L. Bioorg. Med. Chem. 1998, 6, 1127–52.
(25) Stockwell, B. R. Nat. ReV. Genet. 2000, 1, 116–25.
(26) Dobson, C. M. Nature 2004, 432, 824–8.
(27) Stockwell, B. R. Nature 2004, 432, 846–54.
(28) Spring, D. R. Chem. Soc. Re.V 2005, 34, 472–82.
(29) Eggert, U. S.; Mitchison, T. J. Curr. Opin. Chem. Biol. 2006, 10, 232–7.
(30) Walsh, D. P.; Chang, Y. T. Chem. ReV. 2006, 106, 2476–530.
(31) Schreiber, S. L. Science 2000, 287, 1964–9.
(32) Ding, S.; Schultz, P. G. Curr. Top. Med. Chem. 2005, 5, 383–95.
(33) Marcaurelle, L. A.; Johannes, C. W. Prog. Drug Res. 2008, 66 (187),
189–216.
(51) Dinsmore, C. J.; Bogusky, M. J.; Culberson, J. C.; Bergman, J. M.;
Homnick, C. F.; Zartman, C. B.; Mosser, S. D.; Schaber, M. D.;
Robinson, R. G.; Koblan, K. S.; Huber, H. E.; Graham, S. L.; Hartman,
G. D.; Huff, J. R.; Williams, T. M. J. Am. Chem. Soc. 2001, 123,
2107–8.
(34) Driggers, E. M.; Hale, S. P.; Lee, J.; Terrett, N. K. Nat. ReV. Drug
DiscoV. 2008, 7, 608–24.
(35) Deber, C. M.; Madison, V.; Blout, E. R. Acc. Chem. Res. 1976, 9,
106–113.
(52) Dathe, M.; Nikolenko, H.; Klose, J.; Bienert, M. Biochemistry 2004,
43, 9140–50.
(36) Fairlie, D. P.; Abbenante, G.; March, D. R. Curr. Med. Chem. 1995,
2, 654–686.
(53) Udugamasooriya, G.; Saro, D.; Spaller, M. R. Org. Lett. 2005, 7, 1203–6.
(54) Charpentier, B.; Dor, A.; Roy, P.; England, P.; Pham, H.; Durieux,
C.; Roques, B. P. J. Med. Chem. 1989, 32, 1184–90.
(55) Rizo, J.; Gierasch, L. M. Annu. ReV. Biochem. 1992, 61, 387–418.
(56) Craik, D. J.; Simonsen, S.; Daly, N. L. Curr. Opin. Drug DiscoV.
DeVel. 2002, 5, 251–60.
(37) Tyndall, J. D.; Fairlie, D. P. Curr. Med. Chem. 2001, 8, 893–907.
(38) Clardy, J.; Walsh, C. Nature 2004, 432, 829–37.
(39) Wessjohann, L. A.; Ruijter, E.; Garcia-Rivera, D.; Brandt, W. Mol.
DiVers. 2005, 9, 171–86.
(40) Patton, G. C.; van der Donk, W. A. Curr. Opin. Microbiol. 2005, 8,
543–51.
(57) Shibata, K.; Suzawa, T.; Soga, S.; Mizukami, T.; Yamada, K.; Hanai,
N.; Yamasaki, M. Bioorg. Med. Chem. Lett. 2003, 13, 2583–6.
(58) Tugyi, R.; Mezo, G.; Fellinger, E.; Andreu, D.; Hudecz, F. J. Pept.
Sci. 2005, 11, 642–9.
(41) Fung, S.; Hruby, V. J. Curr. Opin. Chem. Biol. 2005, 9, 352–8.
(42) Craik, D. J.; Cemazar, M.; Daly, N. L. Curr. Opin. Drug DiscoV. DeVel.
2006, 9, 251–60.
(43) Kopp, F.; Marahiel, M. A. Nat. Prod. Rep. 2007, 24, 735–49.
(44) Turner, R. A.; Oliver, A. G.; Lokey, R. S. Org. Lett. 2007, 9, 5011–4.
(45) Scott, C. P.; Abel-Santos, E.; Wall, M.; Wahnon, D. C.; Benkovic,
S. J. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 13638–43.
(46) Tavassoli, A.; Benkovic, S. J. Nat. Protoc. 2007, 2, 1126–33.
(47) Gilon, C.; Halle, D.; Chorev, M.; Selinger, Z.; Byk, G. Biopolymers
1991, 31, 745–50.
(59) Illuminati, G.; Mandolini, L. Acc. Chem. Res. 1981, 14, 95–102.
(60) Woodward, R. B.; et al. J. Am. Chem. Soc. 1981, 103, 3213–3215.
(61) Davies, J. S. J. Pept. Sci. 2003, 9, 471–501.
(62) Blankenstein, J.; Zhu, J. Eur. J. Org. Chem. 2005, 2005, 16.
(63) Liau, B. B.; Gnanadesikan, V.; Corey, E. J. Org. Lett. 2008, 10, 1055–7.
(64) Besser, D.; Olender, R.; Rosenfeld, R.; Arad, O.; Reissmann, S. J.
Pept. Res. 2000, 56, 337–45.
(48) Cherney, R. J.; Wang, L.; Meyer, D. T.; Xue, C. B.; Wasserman, Z. R.;
Hardman, K. D.; Welch, P. K.; Covington, M. B.; Copeland, R. A.;
Arner, E. C.; DeGrado, W. F.; Decicco, C. P. J. Med. Chem. 1998,
41, 1749–51.
(65) Haddadi, M. E.; Cavelier, F.; Vives, E.; Azmani, A.; Verducci, J.;
Martinez, J. J. Pept. Sci. 2000, 6, 560–70.
(66) Taunton, J.; Collins, J. L.; Schreiber, S. L. J. Am. Chem. Soc. 1996,
118, 10412–10422.
(49) Gudmundsson, O. S.; Vander Velde, D. G.; Jois, S. D.; Bak, A.;
Siahaan, T. J.; Borchardt, R. T. J. Pept. Res. 1999, 53, 403–13.
(50) Gudmundsson, O. S.; Jois, S. D.; Vander Velde, D. G.; Siahaan, T. J.;
Wang, B.; Borchardt, R. T. J. Pept. Res. 1999, 53, 383–92.
(67) Li, C.-J.; Chan, T.-H. Organic reactions in aqueous media; Wiley
and Sons: New York, 1997.
(68) Snyder, T. M.; Tse, B. N.; Liu, D. R. J. Am. Chem. Soc. 2008, 130,
1392–401.
9
15612 J. AM. CHEM. SOC. VOL. 130, NO. 46, 2008